Stockscreener 앱 받기
6.00
3.27%
0.19
시간 외 거래:
6.00
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV - TipRanks
Verrica Pharmaceuticals (NASDAQ: VRCA) director awarded 16,000 stock options at $6.04 - Stock Titan
Director at Verrica (NASDAQ: VRCA) receives 16,000 stock options - Stock Titan
Verrica (VRCA) director Diem Nguyen awarded 16,000 stock options at $6.04 - Stock Titan
Verrica (VRCA) CMO receives 233,840 performance-vested stock options - Stock Titan
Verrica (VRCA) COO receives 171,340 stock options with price hurdles - Stock Titan
Verrica (VRCA) CEO awarded 512,269 options with $15 and $25 vesting hurdles - Stock Titan
Director Gavin Corcoran receives 16,000 Verrica (VRCA) stock options at $6.04 - Stock Titan
Verrica Pharmaceuticals (NASDAQ: VRCA) shareholders approve new equity plan and re-elect directors - Stock Titan
VRCA: YCANTH adoption accelerates, pipeline advances, and cash runway extends into 2027 - TradingView
Number of shareholders of Verrica Pharmaceuticals Inc. – LS:A41A98 - TradingView
Verrica Shares Drop With Jefferies Conference Ahead, Cash Warning Still in Focus - Bez Kabli
Verrica Stock Slips Before Jefferies as Cash Warning Shadows YCANTH Growth - Bez Kabli
VRCA Stock Price, Quote & Chart | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals to present at Jefferies Global Healthcare Conference June 4, 2026 - Pluang
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
VRCA Assumed by HC Wainwright & Co. -- Buy Rating Announced - GuruFocus
H.C. Wainwright Initiates Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Announces Target Price $12 - Moomoo
Verrica Pharmaceuticals (VRCA) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Sees Modest Stock GainRevenue Per Share - Newser
Earnings Call Summary | Verrica Pharmaceuticals(VRCA.US) Q1 2026 Earnings Conference - 富途牛牛
Number of shareholders of Verrica Pharmaceuticals Inc. – LSX:A41A98 - TradingView
Verrica Pharmaceuticals (VRCA) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesCrowd Risk Alerts - Newser
Verrica Expands YCANTH Sales as Wart Trials Advance - MyChesCo
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: Verrica Pharmaceuticals Q1 2026 shows revenue growth - Investing.com Nigeria
Verrica Pharmaceuticals Q1 earnings call highlights - MSN
Verrica Pharmaceuticals Inc. (VRCA) reports Q1 loss, tops revenue estimates - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2026 Earnings Call Transcript - Insider Monkey
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call - Sahm
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Sahm
Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives - Sahm
Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially - MSN
Verrica (VRCA) Q1 2026 Earnings Transcript - AOL.com
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlig - GuruFocus
Dermatology drug developer Verrica to present at Nasdaq investor event - Stock Titan
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 2026 Growth for YCANTH - GuruFocus
Verrica Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Q1 Earnings Call Highlights - inkl
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 Revenue Growth - GuruFocus
VRCA: Record Q1 growth for YCANTH, pipeline progress, and global expansion drive positive outlook - TradingView
Verrica Pharmaceuticals 1Q Rev $5.02M >VRCA - Moomoo
Verrica Pharmaceuticals (VRCA) Q1 2026: EPS Not Disclosed (Est - GuruFocus
VRCA: Record YCANTH growth, robust pipeline progress, and strong cash position highlight Q1 2026 - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
[10-Q] Verrica Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum - ChartMill
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Verrica (NASDAQ: VRCA) Q1 revenue hits $5.0M as YCANTH demand grows - Stock Titan
MSN Money - MSN
1.27%
1.43%
자본화:
|
볼륨(24시간):